The U.S. peptide therapeutics market size was estimated at USD 73 billion in 2025 and is projected to be worth around USD 150.46 billion by 2035, expanding at a CAGR of 7.5% from 2026 to 2035. The formulations fuelled by the tech intervention are attracting more value in the market. The targeted cancer therapy promotes the necessary expansion of the market in oncology.

U.S. Peptide Therapeutics Market Statical Scope

The manufacturing settings adopting sustainable approaches are bolstering the footprint and value of the market with effective automation in the purification standard process. The rise in modern peptide classes is expanding the rows for small peptides, securing a big share in the market.

The fine investments in the R&D sector, mainly for GLP-1, are driving innovation and fueling qualified expansion to deliver precision to healthcare. The dominance of applications is unlocking the diversified potential of the market by providing best-in-class solutions to the critical conditions.

U.S. Peptide Therapeutics Market Share, By Type Outlook, 2025 (%)

• Innovative - The innovative segment held 72% of the share due to the wide range of specializations in the treatment that pushes the market towards innovative developments to meet the critical healthcare space and targeted therapies. The dynamic formulation role supports the innovations in the peptide solutions.
• Generic - The generic segment acquired 28% of the share due to its long-standing effectiveness and usage compared to the patented drugs. The FDA's framework supports the generic synthetic peptides with the same seriousness towards the branded drugs.

U.S. Peptide Therapeutics Market Share, By Application Outlook, 2025 (%)

• Cancer - The cancer segment held 28% of the share due to the arrival of theranostic peptide comfort that saves time in therapy and imaging. The peptide-related vaccines add one more value to the cancer vaccine portfolio. The prominent role of the peptides in eliminating cancer tumor cells accelerates growth in the market.
• Metabolic Disorders - The segment covered 20% of the share due to the growing patient traffic, elevating the number of targeted peptide treatments. The speedy approvals for specialized peptide treatments for metabolic condition is driving promising and qualified results.
• Neurological Disorders - The segment held 12% of the share due to the growing neurodegenerative condition that demands massive use of peptides for supporting processes such as oxidative stress and inflammation. The research space is promoting the neuropeptides for ischemic stroke, Parkinson's, Alzheimer's and Hunginton's.

U.S. Peptide Therapeutics Market Share, By Route of Administration Outlook, 2025 (%)

• Parenteral Route – The parenteral route segment covered 80% of the share with the impeccable dominance of GLP-1, driving more potential to the route and delivering growth to the injectable peptide. The transitions in the self-administration featuring SC bolus injections encouraged the segmental market growth.
• Oral Route – The segment held 12% of the share as it's an ideal option for the rising chronic condition. The modernization in double-bridged peptides promotes advancement in the segmental market with tough fight to gastrointestinal ecosystem.
• Mucosal – The segment acquired 4% of the share with great emphasis on oral mucosal, which holds remarkable recognition in bioadhesive films and patches. This highlights the role of sustained release of peptides. The nose-to-brain delivery accelerates the demand for the mucosal route.

U.S. Peptide Therapeutics Market Share, By Synthesis Technology Outlook, 2025 (%)

• Solid-phase Peptide Synthesis (SPPS) - The SPPS segment held 55% of the share, as modern automated SPPS systems have evolved the manufacturing space that supports the critical peptides manufacturing with more speed and precision. While the Fmoc-related SPPS is an advanced boon to the segmental market.
• Recombinant DNA Technology - The segment covered 25% of the share due to its greener approach, featuring microbial fermentation that utilizes rDNA technology. The technology enables the synthesis of lengthy peptides with no hassle.
• Hybrid - The segment held 10% of the share due to the critical treatments demanding long-chain peptide drugs. The growing metabolic and cancer cases are accelerating the demand for the same, along with the specialized production process.

North America Peptide Therapeutics Market Share, By Type of Manufacturers Outlook, 2025 (%)

• Outsourced - The outsourced segment acquired 62% of the share due to the rising technical requirements, only handled by the CDMOs, with more space to peptide drugs' end-to-end production. The rising number of assignments accelerates the accessibility of the drugs as well as the growth in the market segment.
• Inhouse - The segment covered 38% of the share due to the solid and confident base of recombinant DNA technology, managing a massive production chain. The smart strategy of the inhouse members helps manage the critical synthesis techniques.

Top Companies in the North America Peptide Therapeutics Market

• Eli Lilly and Company
• Pfizer Inc.
• Amgen Inc.
• Takeda Pharmaceutical Company Limited
• AstraZeneca
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Novo Nordisk A/S
• GSK plc
• Ironwood Pharmaceuticals, Inc.
• Radius Health, Inc.
• Ipsen Pharma

Segments Covered in the Report

By Type

• Innovative
• Generic

By Application

• Metabolic Disorders
• Cancer
• Neurological Disorders
• Gastrointestinal Disorders
• Cardiovascular Disorders
• Pain
• Infectious Disease
• Renal Disorders
• Dermatological Disorders
• Respiratory Disorders
• Others

By Route of Administration

• Parenteral Route
• Oral Route
• Mucosal
• Pulmonary
• Others

By Synthesis Technology

• Recombinant DNA Technology
• Solid-Phase Peptide Synthesis (SPPS)
• Hybrid
• Liquid-Phase Peptide Synthesis (LPPS)
• Others

By Type of Manufacturers

• Inhouse
• Outsourced